Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 16

Trial Status

Completed1
Recruiting1
Terminated1
Other3

Role Distribution

Principal Investigator6
PI Rate100%

Activity Timeline

Clinical Trials (6)

NCT07337525Phase 1Recruiting
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Advanced Malignant Solid TumorSolid Tumor Cancer
PrincipalinvestigatorStart date: 2026-02-13
NCT03537690Phase 1Active Not Recruiting
FID-007 in Treating Participants With Advanced Solid Tumors
Advanced Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
PrincipalinvestigatorStart date: 2018-05-25
NCT03257761Phase 1Active Not Recruiting
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
Extrahepatic Bile Duct Adenocarcinoma, Biliary TypeGallbladder Adenocarcinoma, Biliary TypeMetastatic Pancreatic Adenocarcinoma+25 more
PrincipalinvestigatorStart date: 2018-02-07
NCT01302405Phase 1Terminated
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
Advanced Solid Tumors
Principalinvestigator
NCT01762410Phase 1Suspended
Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Advanced Refractory Solid Tumors
Principalinvestigator

Research Network

Collaboration Network

9 collaborators·36 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jason Henry, MD

Sarah Cannon Research Institute at HealthONE

Related
1 trials

Shared therapeutic areas:

Solid Tumor

Worked with same sponsors:

Sirnaomics
Collaborated on 1 trial
Similarity Score14%

Conor Steuer, MD

Emory University

Related
3 trials

Shared therapeutic areas:

Solid Tumor

Worked with same sponsors:

National Cancer Institute (NCI)Sirnaomics
Collaborated on 1 trial
Similarity Score14%

Hani Babiker, MD

Mayo Clinic

Related
1 trials

Shared therapeutic areas:

Solid Tumor

Worked with same sponsors:

Sirnaomics
Collaborated on 1 trial
Similarity Score14%

Michael Cecchini, MD

Yale University

Related
1 trials

Shared therapeutic areas:

Solid Tumor

Worked with same sponsors:

Sirnaomics
Collaborated on 1 trial
Similarity Score14%

Angela Alistar, MD

Atlantic Health System

Related
1 trials

Shared therapeutic areas:

Solid Tumor

Worked with same sponsors:

Sirnaomics
Collaborated on 1 trial
Similarity Score14%

Andrae Vandross, MD

NEXT Oncology

Related
1 trials

Shared therapeutic areas:

Solid Tumor

Worked with same sponsors:

Sirnaomics
Collaborated on 1 trial
Similarity Score14%

Zhaohui Jin, MD

Mayo Clinic

Related
1 trials

Shared therapeutic areas:

Solid Tumor

Worked with same sponsors:

Sirnaomics
Collaborated on 1 trial
Similarity Score14%

Christina Wu, MD

Mayo Clinic

Related
1 trials

Shared therapeutic areas:

Solid Tumor

Worked with same sponsors:

Sirnaomics
Collaborated on 1 trial
Similarity Score14%

Aung Naing, Md

M.D. Anderson Cancer Center

Related
16 trials

Shared therapeutic areas:

Advanced Malignant Solid NeoplasmSolid TumorAdvanced Solid Tumors

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score3%

You Lu, MD

West China Hospital

Related
18 trials

Shared therapeutic areas:

Advanced Solid TumorsSolid Tumor
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (6)

Showing 6 of 6 trials

NCT07337525Phase 1PrincipalInvestigator

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

Advanced Malignant Solid TumorSolid Tumor Cancer
Recruiting
NCT05037149Phase 1PrincipalInvestigator

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

Solid Tumor
Completed
NCT03537690Phase 1PrincipalInvestigator

FID-007 in Treating Participants With Advanced Solid Tumors

Advanced Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
Active Not Recruiting
NCT03257761Phase 1PrincipalInvestigator

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

Extrahepatic Bile Duct Adenocarcinoma, Biliary TypeGallbladder Adenocarcinoma, Biliary TypeMetastatic Pancreatic Adenocarcinoma+25 more
Active Not Recruiting
NCT01302405Phase 1PrincipalInvestigator

Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors
Terminated
NCT01762410Phase 1PrincipalInvestigator

Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors

Advanced Refractory Solid Tumors
Suspended

All 6 trials loaded